UPPER EXTREMITY DVT IN ONCOLOGICAL PATIENTS: ANALYSIS OF RISK FACTORS. DATA FROM THE RIETE REGISTRY
M. Monreal1, *, F.J. Munoz2, V. Rosa3,
C. Romero4, P. Roman5, P. Di Micco6, P. Prandoni7
1Internal Medicine Division, Hospital of Germans Trias i Pujol University, Badalona, Spain 2Internal Medicine Division, Hospital de Mollet, Barcelona, Spain 3Internal Medicine Division, Hospital Vega Baja, Orihuela, Alicante, Spain 4Internal Medicine Division, Hospital Costa del Sol, Marbella, Malaga, Spain 5Internal Medicine Division, General Hospital of Requena, Requena, Valencia, Spain 6Internal Medicine Division, Buonconsiglio Fatebenefratelli Hospital, Naples, Italy 7Medical and Surgical Science, Medical Clinic II, University of Padova, Padova, Italy
Abstract. Aim: The aim of the study is to up date informations on the
clinical characteristics and outcome of patients with upper-extremity deep vein thrombosis
(DVT) from the Informatised Registry on Venous Thromboembolism (RIETE). Methods: RIETE
is an ongoing registry of consecutive patients with symptomatic, objectively confirmed,
acute venous thromboembolism. In this analysis the clinical characteristics and 3-month
outcome of all cancer patients with upper-extremity DVT were evaluated. Results: Up
to February 2006, a total of 14,391 patients with symptomatic, objectively confirmed acute
venous thromboembolism had been enrolled in RIETE. Of the 2,945 patients with active
cancer 196 (6.7%) had arm DVT: 104 had catheter-associated DVT. Most cancer patients with
arm DVT were males, younger than 65, and had a low incidence of additional risk factors or
underlying diseases. Twenty of them (10%) had symptomatic pulmonary embolism (PE). Most
patients were treated with low-molecular-weigh heparin, both initially (94%) and after
discharge (75%). During the 3-month follow-up period 12 patients (6.1%) developed VTE
recurrences (PE 6, DVT 6), 8 (4.1%) had major bleeding (fatal in 3), 43 (22%) died. Conclusions:
Our data from the RIETE registryshow that upper limb DVT is a serious
complication in patients with cancer, with a high incidence of recurrences and bleeding
complications.